DailySand tracks obesity treatment across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where obesity treatment appears in today's cross-sector intelligence briefing.
2 items across 2 digests
Eli Lilly's combo obesity treatment combining eloralintide with tirzepatide showed positive weight-loss results in mid-stage trials, with Phase 3 trials planned for end of year. Success in obesity therapeutics expands Lilly's GLP-1 portfolio and addresses a large market opportunity.
Read original →Real-world study data shows Novo's Wegovy oral pill maintains weight loss efficacy compared to weekly injections, potentially allowing patients to discontinue injections for more convenient pill-based treatment. This expands addressable markets for obesity treatments by removing injection barriers to adoption.
Read original →
DailySand